Company news
Nurexone Biologic Inc (TSXV:NRX) news
Every Nurexone Biologic Inc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into Ontario
April 22, 2025
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
April 9, 2025
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
April 4, 2025
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
March 14, 2025
NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock
March 10, 2025
NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award
February 27, 2025
NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award
February 27, 2025
NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock
February 19, 2025
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
February 14, 2025
Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX)
January 22, 2024
The Watchlist by The Market Herald Releases New Interviews with NurExone Biologic and SuperBuzz Discussing Their Latest News
September 13, 2023
NurExone Announces Appointment of New Director and Provides Corporate Updates
July 7, 2023
NurExone Engages Investor Relations Service Provider
May 12, 2023
NurExone Announces Equity Incentive Plan Grants and Director Resignation
May 8, 2023
United States Patent Office Allows Patent to Exosome Biomedical Company NurExone
January 12, 2023
NurExone Issues Annual Shareholder Letter
December 15, 2022
NurExone Announces Completion of Securites for Debt Settlement
December 7, 2022
Update: NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules
December 1, 2022
NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules
November 30, 2022
NurExone Announces Securities for Debt Settlement
November 24, 2022
NurExone Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 24, 2022
NurExone Announces Completion of Securities for Debt Settlements
November 8, 2022
NurExone Announces Plan to Submit Pre-Investigational New Drug Meeting Request to U.S. Food and Drug Administration
November 2, 2022
NurExone Announces Productivity and Quality Pilot Results of Patent-Pending Process for 3D Scaled Up Exosome Production
October 26, 2022
NurExone Biologic to Participate in 2022 Bio-Europe Conference
October 20, 2022
UPDATE: NurExone Signs Letter of Intent with Nanometrix for Its Exosome and Cargo Molecular Profiling AI-Driven Technology
October 12, 2022
NurExone Signs Letter of Intent with Nanometrix For its Exosome and Cargo Molecular Profiling AI-Driven Technology
October 12, 2022
NurExone Announces Scientific Survey Results of Proprietary Exosome-based Technology
October 4, 2022
NurExone Announces Additional Securities for Debt Settlement
October 3, 2022
NurExone Announces Letter of Intent for International Strategic Collaboration with denovoMATRIX Towards Large-Scale Exosome Production
September 7, 2022
NurExone Announces Securities Issuing at Premium over Current Share Price to Settle EnerSpar's Debts Prior to RTO Transaction
September 1, 2022
NurExone Reports Second Quarter 2022 Financial Results and Provides Business Update
August 25, 2022
James Richardson, the Former CEO of EnerSpar, Updates Shareholders After the Completion of RTO with NurExone Biologic
August 9, 2022
NurExone Announces Sponsorship and Participation in Gordon Research's 2022 Extracellular Vesicles Conference in Maine, U.S.
July 25, 2022
NurExone Exosomes to Be Used in Cutting Edge Molecular Research at Hebrew University's Burstyn-Cohen Lab
July 19, 2022
NurExone Provides Corporate Update
July 13, 2022
NurExone to Collaborate with Polyrizon for Intranasal Administration of Cutting-Edge Exosome-Therapy
July 11, 2022
NurExone to Host Investor Webinar on Thursday, July 14, 2022
July 7, 2022
NurExone Biologic Inc. Retains Services of Thesis Capital Inc
July 6, 2022
NurExone Biologic Inc. Opens the Market
July 5, 2022
NurExone Biologic Inc. to Begin Trading on TSX Venture Exchange and Retains Market Maker
June 22, 2022